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Abstract
The terrestrial nematode, Caenorhabditis elegans, is an invaluable model organism for the study
of molecular and cellular processes due to their small size, rapid generation time, easy
cultivation, and invariant cell number. Additionally, 40% of genes known to be associated with
human disease have clear orthologs in the C. elegans genome. In C. elegans genetics research,
microinjection of genetic material into the worms is critical. Although an established technique,
manual microinjection is tedious, low-throughput, and requires an expert researcher. This thesis
details a novel microfluidic device designed to perform high-throughput microinjection. This
two-layer, PDMS-based chip integrates microfluidic elements to control worm sorting, reduction
of immobilization time and stress, and novel on-chip microinjection using only a positive
pressure source. Our project aim is to increase microinjection efficiency, consistency, and
accessibility to researchers of all experience levels in order to advance genetics research and
genetic engineering technology in C. elegans. Preliminary results are promising, as our on-chip
microinjection device has been able to successfully inject dye into C. elegans animals.
Keywords: C. elegans, Microinjection, Microfluidics, On-chip Microinjection, Genetics
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1.

Chapter 1: Introduction
1.1.

Motivation
The terrestrial nematode, Caenorhabditis elegans, is an invaluable model
organism for the study of molecular and cellular processes due to its small size,
rapid generation time, easy cultivation, sequenced genome, and invariant cell
number. Additionally, 40% of genes known to be associated with human disease
have clear orthologs in the C. elegans genome. In C. elegans genetics research,
microinjection of genetic material into the worms is critical to the creation of
transgenic animals. Although an established technique, manual microinjection is
tedious, low-throughput and requires an expert, making it a major rate limiting
step in C. elegans genetic research. Our project goal was to utilize microfluidic
technology to increase microinjection efficiency, consistency, and accessibility to
researchers of all experience levels in order to advance genetics research and
genetic engineering technology in C. elegans.

1.2.

C. elegans background and basics
C. elegans is a type of terrestrial, transparent nematode that grows to be about 1
mm in length and 30-45µm in width. While generally found in temperate soil
environments, these worms can be easily cultivated and studied in the lab.
C. elegans has served as an invaluable genetics model organism since the 1970’s
due to the high degree of similarity found between its cellular and molecular
processes (i.e. morphogenesis, biochemical signaling pathways, protein coding
genes) and those found in humans. The C. elegans genome contains orthologs for
60-80% of human genes, 40% of which are related to human disease states such
as cancer1. C. elegans has also served as an excellent medium for optimizing
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Corsi et al. "A transparent window into biology: a primer on Caenorhabditis elegans." Genetics,
(2015).
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genetic engineering technologies (i.e. CRISPR/Cas 9) as genetics research has
been conducted on them for decades and knowledge of their genome is well
established.
In addition to its value as a genetics model organism, C. elegans possess a number
of favorable properties making it an excellent research subject. Some of these
characteristics include:
● Optical transparency
● Small size
● Simple anatomy with fully mapped cell lineages
● Easy cultivation (grown in petri dishes)
● Quick generation time (3 days at 23℃)
● Hermaphroditic (self-fertilization useful in genetics research)
● Completely sequenced genome
1.3.

Creation of transgenic C. elegans animals using microinjection
In many C. elegans genetics labs, researchers attempt to alter, disrupt, or replace
genes in order to study their function. One way to alter the C. elegans genome for
research purposes is to manually microinject genetic material into a worm’s
newly forming oocytes. The genetic material can range from simple plasmids to
genetic engineering constructs and proteins such as CRISPR/Cas 9. For example,
in Dr. Leilani Miller’s lab at Santa Clara University (SCU), certain sequences of
the C. elegans genome are edited by injecting plasmids coding for a guided
CRISPR/Cas 9 construct. This CRISPR/Cas 9 complex cuts and edits certain
sequences in the worm genome to disrupt the phosphorylation sites of a particular
transcription factor. This allows her to study the role that phosphorylation of that
particular protein plays in a biochemical signaling pathway.

1.4.

Limitations of manual microinjection
To emphasize the tedious nature of manual microinjection, we have outlined the
key steps of this process below:
2

● Pull a very small glass capillary (external diameter = 1 mm,
internal diameter = 0.58 mm) into an even smaller glass
microinjection needle (tip diameter ~ 1µm)
● Load the needle with injection mix
● Transfer worm to drop of injection oil on a desiccated agarose pad
● Manually rotate wriggling 1mm x 40µm worm into the correct
orientation for injection
● Manually press the worm against the agarose injection pad so that
it will adhere and hold still (without popping the worm)
● Manually puncture the worm’s gonad and flood its distal tip with
injection mix
● Remove the worm before it desiccates on the injection pad and
proceed with recovery process
Although this is an abbreviated list of the microinjection procedure, we hope that
it is now apparent how delicate and labor intensive this process can be and why
many researchers spend years mastering this technique. To see a visual depiction
of the manual microinjection process, see Appendix A.
1.5.

Critical elements for a successful microinjection
To properly inject genetic material into a worm, a researcher must insert the
needle into the worm at the correct angle, on the correct side of their body, and
apply the perfect amount of force to barely puncture the cuticle of the worm and
flood its gonad with injection mixture. With this delicate procedure, it is easy for
a researcher to accidentally kill the animal by pushing too hard, inserting the
needle at the wrong angle, or by using a blunt needle
To successfully create transformants, the injected worms must be healthy young
adult hermaphrodites with plenty of developing oocytes in their gonad2. An
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Evans et al. “Transformation and microinjection.” WormBook, (2006).
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optimal injection will puncture and flood the distal tip of one or both of the
worm’s gonads with the desired genetic construct (Figure 1) 3.

Figure 1. Injection of genetic material into distal tip of C. elegans gonad.
(A) Schematic showing proper microneedle angle and insertion point into
worm gonad for a successful microinjection of genetic material. (B) Closeup of worm gonad showing insertion of microneedle tip into the syncytium
of the distal tip of the gonadal arm. Image adapted from Rieckher et al
(2017)3.

Successful transformation of germ-line cells is dependent on injection of genetic
material into the cytoplasmic core of the syncytium located at the distal tip of the
hermaphrodite’s gonad4 (Figure 1B). This allows the injected genetic material to
become incorporated into the new eggs as their newly forming plasma membranes
encapsulate both the oocyte nuclei and the cytoplasm containing the injected
genetic material. Incorporation of genetic material into the newly formed oocytes
produces successful genetic transformants.

3

Rieckher et al. “Generation of C. elegans Transgenic Animals by DNA Microinjection.” Bio-protocol (2017).
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Given the detailed nature of the microinjection procedure coupled with the
microscopic size of the target injection site, microinjection is a major rate limiting
step in C. elegans genetics labs around the world.
1.6.

A primer on microfluidic technology
Microfluidic technology allows the user to interact with various systems at a
micron scale. Microfluidic chips have four main advantages: miniaturization,
increased throughput, low-cost, and potential for automation. Channel dimensions
are typically <100 μm, providing working volumes within the nanoliter range—
well within the dimensions of C. elegans.
1.6.1.

Fluid properties
Using an array of channels and valves, users can direct the way that fluid
flows through microfluidic chips. The primary advantage of working with
fluids on the micron scale is that the fluids experience laminar flow, this
means that its fluid dynamics are more easily controlled and understood.
Additionally, at this scale, researchers are able to use reduced reagent
volumes which yields a lower overall cost.

1.6.2.

Material properties
Microfluidic chips are primarily made of polydimethylsiloxane (PDMS),
an optically clear rubber. Some of the advantages of utilizing PDMS are
its flexibility (Young’s modulus can be modified by altering the mixture
of crosslinker to prepolymer), optical transparency, gas permeability,
biocompatibility, and relatively low cost.

1.6.3.

Application of microfluidics to C. elegans research
Made from PDMS, microfluidic devices are transparent, permeable to gas,
non-toxic, and inert; therefore, they are appropriate for biological research.
Microfluidic devices maintain controlled flows and allow for easy

5

handling and manipulation of C. elegans animals5, making some
techniques more accessible and previously impossible ones possible.
1.7.

Existing microfluidic microinjection technology
Before embarking on our design project, we isolated three critical components for
successful C. elegans microinjection: alignment, immobilization, and lastly,
microinjection. We conducted a literature review of current microfluidic
technologies that address these steps and their application in C. elegans research.
1.7.1.

Microfluidic alignment of C. elegans
In 2016, researchers from York University and Mount Sinai Hospital in
Canada created a device for orientation and multidirectional imaging of C.
elegans. Ultimately, they sought to provide lateral and longitudinal
control. In order to achieve this, they incorporated electrotaxis technology
into their chip with a rotatable glass capillary that controlled radial
alignment6. As shown in Figure 2, the worm first experiences the electric
field that orients it head-to-tail. Using a direct current, they oriented C.
elegans locomotion towards the cathode. Then, using fluid flow, a single
C. elegans animal enters the imaging channel where suction immobilizes
the worm from above and the capillary attaches to its head7.

Figure 2. Schematic representation of a microfluidic chip that uses a glass actuator to
rotate a single worm7.
5

San-Miguel et al. “Microfluidics as a Tool for C. elegans Research.” WormBook, (2013).

Ardeshiri et al. “A Hybrid Microfluidic Device for On-demand Orientation and Multidirectional Imaging of C.
elegans Organs and Neurons.” Biomicrofluidics, (2016).
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This novel control technique allows for multidirectional manipulation of
C. elegans animals. While the research with this microfluidic device
focuses on imaging of organs and neurons, the control method
demonstrates great potential for aligning and directing microinjector
needles into the gonad of a worm.
1.7.2.

Microfluidic immobilization of C. elegans
There are multiple existing microfluidic technologies that can effectively
immobilize C. elegans. As seen in the microfluidic chip from Figure 2,
one method for immobilization is suction. In that chip, once the worm was
in the correct region, suction across the top of the channel would keep the
worm in place. Researchers from Wuhan National Laboratory used a
slightly different method for immobilization that also utilizes suction.
However, this method, depicted in Figure 3, makes use of a supplementary
suction in an open chamber8.

Figure 3. Microfluidic immobilization of worm head and tail using suction. (B) Worm is
loaded into immobilization region as its head is suctioned into the first inlet. (C) The worm is
immobilized when the flailing tail is caught in the second suction chamber. The suction applied to
the worm’s head and tail pulls it taut for injection. Image adapted from [8].

Zhao et al. “Microfluidic Chip-Based C. elegans Microinjection System for Investigating Cell-Cell
Communication In Vivo.” Biosensors and Bioinformatics, (2013).
8
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As the worm reaches the end of the flow channel, its end is caught by the
supplementary suction in Figure 3b. Then, after the worm is pushed out of
the flow channel into the open chamber, the body of the worm is
immobilized by the main suction and the other end is caught by the second
supplementary suction as seen in Figure 3c. This suction method
effectively immobilizes the worm for an external microinjection system to
inject the worm.
1.7.3.

Microfluidic microinjection of C. elegans
Also, in 2016, three researchers from the Department of Mechanical
Engineering at McGill University in Canada developed a microfluidic chip
that could perform high-speed, automated microinjection of C. elegans.
This novel device used pneumatic valves to control loading,
immobilization, and injection. Figure 4 below shows the microinjection
region of the chip—laminar fluid flow transports a single worm across the
injection channel, a pneumatic valve pins the worm in place, a needle
enters through the injection channel, the needle injects the worm, and then
the immobilization valve is released, allowing fluid flow to transport the
worm out of the microinjection region.

8

Figure 4. Microinjection of C. elegans animals within a microfluidic chip. (A) Worm brought into
microinjection chamber utilized positive pressure flow through the flow channel. (B) Worm reaches
microinjection region and is immobilized against PDMS teeth using a control valve located on top of the
animal. (C) Microinjection needle (labelled as “pipette tip”) brought into microinjection chamber alongside
worm. External micromanipulator controls needle tip, targets gonad, and injects worm with desired genetic
construct. (D) Once injected, worm is released from the immobilizing control valve and moved forward due
to positive pressure from fluid flow.

In a proof of concept experiment, researchers injected 200 C. elegans
animals, obtaining an average injection rate of 6.6 worms per minute.
They obtained a pre-sorting success rate of 77.5% (successfully injected
worms compared to total number of injected worms). A successful
injection was obtained if they loaded a single worm into the injection
chamber and then witnessed the worm body expand with the injection
itself9. Additionally, they found no statistical difference in lifespan
between a control population and the injected worm population. However,

9

Song et al. “A Microfluidic Device for Automated, High-Speed Microinjection of Caenorhabditis elegans.”
Biomicrofluidics, (2016)
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this device lacked any type of worm orientation and they did not inject
genetic material to test for a successful transformation rate.
1.8.

Critique of current technologies
In evaluating the state of current microfluidic technology and its applications in
manipulating and injecting C. elegans, we identified three critical design elements
we could address with our device: (1) orientation, (2) immobilization, and (3)
microinjection.
The first design element we identified was orientation of the worms for
microinjection. However, we decided not to pursue this area of design
development for two reasons: (1) many well-developed, microfluidic orientation
elements already exist and could be easily integrated into any C. elegans
microfluidic chip, and (2) we intend to create a chip whose high-throughput
nature could overcome the barrier of only obtaining a successful injection 33.33%
of the time (the gonad comprises ~33% of the worm’s body cross-section so even
without orientation, the worm would be in the correct orientation ⅓ of the time).
The second design element we identified was worm immobilization. We found
that most microinjection chips utilize immobilization methods that place the
worms under prolonged and extreme stress. Applying continued stress to the
worms increases the probability that they die during injection, decreasing
transformation efficiency. Similarly, complex immobilization strategies decrease
the throughput of these chips, further decreasing injection efficiency. Therefore,
we wanted to design an immobilization element that would reduce the amount of
time the worm was subjected to immobilization stress.
The third design element that we identified was microinjection itself. The
majority of microinjector chips utilized external microinjector elements. That is,
they used a microfluidic chip in conjunction with standard microinjector
equipment like an inverted microscope, micromanipulator, and injection
regulator. While these systems were efficient and consistent in their injections, we
believed that they missed the point of microfluidic technology. Microfluidic
10

technology revolutionizes standard laboratory experiments via miniaturization,
integration, automation, and its high-throughput nature. Shrinking down the scale
can vastly increase the experiment rate and decrease costs. We believe that
previous research missed the mark by simply integrating a microfluidic chip with
a standard microinjection set-up. Instead, the goal should be to create a
microfluidic device that can conduct orientation, immobilization, and
microinjection all on-chip without any external (and expensive) instruments.
1.9.

Project goal
With our objective to design improved immobilization and microinjection
elements identified, we formulated our project objective:
Design a microfluidic device to conduct on-chip immobilization and
microinjection of C. elegans without the aid of any external elements. Our chip
will increase microinjection efficiency, consistency, and accessibility to
researchers of all experience levels to advance genetics research and genetic
engineering technology in C. elegans.

1.10.

Back-up plan
In the event that we were unable to complete our project by the end of the year,
we developed a number of back-up plans.
(1) If we were unable to produce and test a chip that could inject worms, we
would at least create a novel design for an on-chip microinjector that could
be easily integrated with existing immobilization and orientation elements
from other devices.
(2) If we were unable to complete back-up plan (1), we would at least attempt
microinjection using the external microinjection elements that we
possessed in Dr. Leilani Miller’s C. elegans lab at SCU.
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1.11.

Project significance
In the rapidly expanding field of genetics and genetic engineering research, the
manual microinjection process presents a significant rate limiting step. Compared
to manual microinjection, a high-throughput, self-contained microfluidic chip
could increase the rate of successful C. elegans microinjections, increase the
number of researchers able to conduct injections, and reduce the cost of injections
(fewer startup costs for inverted microscopes, micromanipulators, etc). This
technology has the potential to dramatically empower C. elegans laboratories
around the world to conduct human-relevant genetics research and optimization of
genetic engineering technologies.
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2.

Chapter 2: Microfluidic Chip Design and Fabrication
2.1.

Introduction
The goal of the microfluidic chip is to assist in the microinjection process by
immobilizing and orienting worms prior to microinjection. The chip accomplishes
this goal using a variety of regions and microfluidic valves.

2.2.

Key constraints
Constraints were introduced in two forms: those from the utilized lab spaces, and
those imposed by the microfluidic chip itself. Two main lab spaces were used, the
Center for Nanostructures (CNS) and Dr. Emre Araci’s microfluidics lab at SCU.
Regarding the CNS, the primary constraint was a 2:1 resolution ratio of feature
height to feature width. The height of the primary flow layer needed to be 40 μm
to allow for the worms, so features could not be less than 20 μm wide.
2.2.1.

Microfluidic lab vacuum system control
The main constraint of the microfluidic lab was the lack of controllable
vacuum system. Many chips that were investigated required the use of a
vacuum system to immobilize worms prior to injection. Therefore, it was
not possible to use these designs to achieve the immobilization objective.
Similarly, many chip designs utilized a vacuum system to alter the
pressure of the channels the worms flow through. In creating negative
pressure on one side of the worm, the worms would be sucked into smaller
channel widths than their body dimensions normally allow without
causing blockages in the chip.

2.2.2.

Flow channel width versus worm mobility
Flow channel width versus worm mobility needed to be optimized.
Narrow channels would need to afford very little mobility, ensuring that
the worms are held in place properly for injection. However, if the
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channels became too narrow, without the assistance of a vacuum system,
the worms may get stuck in the chip.
2.2.3.

Microinjector membrane thickness
The microinjector membrane is optimized to give acceptable levels of
deflection when under pressure while retaining its ability to grip an
embedded needle. Current designs afford little membrane deflection in
favor of holding the needle in the membrane. Making the membrane too
thick decreases membrane deflection (See Chapter 6) but increases grip
strength on the needle. Decreasing membrane thickness allows for more
deflection but less grip of the needle, potentially allowing the needle to
fall out during injections.

2.3.

Detailed design description
The microfluidic chip has two layers: a control layer and a flow layer. Worms
occupy the flow layer, and the control layer determines how fluid flows through
the chip.

Figure 5. Example AutoCAD design of full microfluidic microinjection chip. Green regions are the flow layer of
the chip. Red regions are control valves in the control layer of the chip
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The chip can be broken down into four main regions: the input, the micropillar
array, the immobilization and injection region, and the outputs.
2.3.1.

Chip input
Worms are loaded into the chip at the input by drawing them into a small
plastic tube (200 μm diameter). This tube is then connected to the output
of a microfluidic cryo tube. The pressure applied to the tube is controlled
either manually or by using an external pressure source. Input pressure
determines the flow rate through the chip.

2.3.2.

Micropillar array
The next region is the micropillar array. The array is designed to separate
clumps of worms, as well as filter out any debris that may have been
generated by the worms or transferred from the worm plates.

Figure 6. AutoCAD design of micropillar array within microfluidic microinjection chip. Micropillars are utilized
to (1) redistribute entering worms and prevent animal clustering, and (2) filter debris to prevent clogging of upcoming
narrow flow channels.

Worms enter the micropillar array in the upper left and exit through the
lower right. Pillars are 100 μm by 100 μm. The design for the micropillar
array is loosely based off an existing design by Song et al. (2016), though
all dimensions were approximated, as we were unable to find exact
micropillar arrays specified in the source papers10. The entrance to the
micropillar array is 120 μm wide, whereas the exit is either 100 μm wide.
Song et al. “A Microfluidic Device for Automated, High-Speed Microinjection of Caenorhabditis elegans.”
Biomicrofluidics, (2016)
10
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We optimized this width so that worms will only load into the primary
flow channel one at a time, making orienting and injecting the worms later
in the chip easier.
2.3.3.

Immobilization channel
The third region of the chip is the immobilization section.

1

2

3

A
B

Figure 7. AutoCAD design of immobilization region of microfluidic microinjection chip. The red numerically
labeled features are in the control layer. The green alphabetically labeled features are in the flow layer.

The section has five main components: the left flow control valve (1), the
upper immobilization valve (2), the right flow control valve (3), the flow
channel (A), and the microinjector membrane (B). Details on how this
section operates can be found in Section 4.3.
2.3.4.

Microinjection region
The microinjection region is located just below the immobilization region
of the chip.
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A

1

B

Figure 8. AutoCAD design of microinjector region of microfluidic microinjection chip. The red numerically
labeled features are in the control layer. The green alphabetically labeled features are in the flow layer.

The microinjector region has two main features: the microinjector channel
(B) and the microinjector valve (1). The flow channel is section A.
2.3.5.

Offloading area
There are two output valves from the offloading area.

1
A
2

B

Figure 9. AutoCAD design of offloading region of microfluidic microinjection chip. The red numerically labeled
features are in the control layer. The green alphabetically labeled features are in the flow layer. The input of valve A
is not shown.
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By turning Valve 2 on and Valve 1 off, flow is directed towards Channel
A. By turning Valve 1 on and valve 2 off flow is directed towards Channel
B. Depending on the predicted success of the microinjection, the worms
can be either directed towards one output or another. At the end of the
outputs for A and B, worms are then collected in tubes outside of the chip.
2.4.

Expected results
Protocols for mask creation, photolithography, and soft lithography are very well
established. Masks are created and printed using a user provided AutoCAD file.
Photolithography results are detailed in all photolithography chemicals’ respective
data sheets. Soft lithography expected results are largely based off Dr. Araci’s
extensive knowledge of soft lithography.

2.5.

Materials and methods
Chips are created via photolithography and soft lithography, and then tested using
a microfluidic multiplexer.

Figure 10. Overview of photolithography and soft lithography procedures. 11 Image adapted from [12].

11

San-Miguel et al. “Microfluidics as a tool for C. elegans research.” WormBook (2013).
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Figure above shows the relationship between molds created via photolithography
(1-3) and chips created from soft lithography (4-6). The processes depicted differ
from our own in that they lack a control layer, thus only one photomask is used
instead of our two.
2.5.1.

Photolithography masks
Mask designs are created using Autodesk’s AutoCAD software. The chips
were designed to have two layers: flow and control. Masks had space for
10 total designs, some unique and some identical.

2.5.2.

Photolithography procedure
Photolithography is completed using SU8-2050 for both the control and
flow layers.
2.5.2.1.

Control layer
Control layers are made to be 50 μm tall using the following
procedure:
1. Spin SU8-2050 at 3100 RPM for 30 seconds
2. Soft bake for 3 minutes at 95°C
3. Expose for 15 seconds
4. Post-exposure bake at 95°C for 4 minutes
5. Develop for 2 minutes 30 seconds in SU8 developer
6. Hard bake using the following parameters: start at 65°C,
end at 160°C, ramp up temperature at 120°C/hour, stop
after 2 hours

2.5.2.2.

Flow layer
Flow layers are 30 μm tall and manufactured via the following
protocol:
1. Spin SU8-2050 at 5000 RPM for 45 seconds
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2. Soft bake for 5 minutes at 95°C
3. Expose for 11 seconds
4. Post-exposure bake at 95°C for 3 minutes
5. Develop for 2 minutes 30 seconds in SU8 developer
6. Hard bake using the following parameters: start at 65°C,
end at 160°C, ramp up temperature at 120°C/hour, stop
after 2 hours
2.5.3.

Soft lithography procedure
Soft lithography is created using PDMS.
2.5.3.1.

Control layer
The control layer is made of 5:1 PDMS to curing agent. PDMS is
poured over the control mold and then degassed. After curing for 1
hour at 80°C, PDMS is separated from the control mold, cut into
individual chips, and hole punched in appropriate locations.

2.5.3.2.

Flow layer
The flow layer is made of 20:1 PDMS to curing agent. The flow
layer mold is placed in the spin coater, PDMS is poured onto the
center of the wafer and spun at 1400 RPM for 1 minute and 15
seconds. PDMS height should be 50 μm. The mold is cured for one
hour at 80°C.

After preparing the layers, the control layer chips are aligned over the flow
layer mold using a microscope. Control channels must be facing down
towards the PDMS of the flow layer. The final assembly is then put back
in the oven to cure for 2+ hours at 80°C. The final chip assembly is then
cut from flow mold, hole punched, and can be stored for later usage.
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2.5.4.

Plasma bonding treatment
Aligned chips must be plasma bonded to a glass substrate prior to testing.
Using a plasma machine, chips and glass substrate are exposed to plasma
for 30 seconds, and then treated surfaces are immediately sandwiched
together. Successful bonding results in an inability to separate the PDMS
chips from glass substrate.

2.5.5.

Microfluidic multiplexer
Microfluidic function is controlled using a Microfluidic Multiplexer linked
to Elveflow software.

2.6.

Results and discussion
Successful completion of chip fabrication is evaluated using three main criteria:
layer alignment, presence of sensitive features, and presence of channel collapse.
Successfully created chips are properly aligned, have all the required sensitive
features, and no channel collapse. Evaluations of this criteria is done using
qualitative observations.
2.6.1.

Layer alignment
Alignment is primarily judged off how the microinjector region valves
overlay on the microinjector flow channel.

Figure 11. Flow and control layer microinjector region alignment. (Left) AutoCAD design showing proposed
alignment of control layer (red) on top of flow layer (green) within the chip microinjector region. (Right) Actual
alignment of control and flow layers within chip.
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Figure 11 shows an example of successful alignment. Valves are below
center of flow region (green), and lowermost completely covers thin
membrane / teeth.
2.6.2.

Sensitive features
The microinjector teeth / membrane area of our chips is the most sensitive
in that they are the most difficult to fabricate. Due to constraints of
photolithography, feature dimensions with an aspect ratio greater than 2
(feature height to feature width) are difficult to fabricate. Current
protocols call for teeth dimensions that are 35 micron tall by 20 micron
wide (aspect ratio of 1.75), which is at the limit of our aspect ratio (2).

Figure 12. Test-filling flow layer of microinjector region with red dye. (Left) Flow layer of microinjector region
prior to filling with fluid. (Right) Microinjector region filled with red dye (shown in grayscale).

Figure 12 shows an instance of failed photolithography. The teeth appear
to present on the left, but fluid reveals that it can flow right over them. The
likely cause is that the developer did not wash all unexposed SU8 out of
the teeth holes, reducing their height and preventing the teeth from plasma
bonding to glass substrate. Chips with thin, continuous membranes do not
see this failure, as it is easier to wash out undeveloped SU8. In our final
design, only chips with thin membranes are used.
2.6.3.

Channel collapse
Channel collapse results in the permanent sealing or collapsing of a
control valve, negatively impacting microfluidic behavior and
controllability.
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Figure 13. Image depicting extreme collapse of microinjector control valve. Valve is collapsed on top of needle
tip embedded in membrane located between microinjection region and worm flow channel. Valve is collapsed as it is
permanently plasma bonded to the floor of the flow layer.

Figure 13 shown above depicts an extreme case of microinjector valve
collapse. Valve collapse can result from a valve being too large to support.
The valve is 1000 μm wide but only 30 μm tall, with no support in the
middle to keep the “roof” from falling down. Collapse may also result
from pressing on the control channels during plasma bonding, resulting in
their collapse and bonding to the glass substrate.

Figure 14. Reversibility of collapsed microinjection control valves under extreme pressure. (Left) Collapsed
microinjector valve before application of pressure. (Right) Restored, non-collapsed microinjector valve after extreme
pressure was applied to flow layer of microinjection region.

Figure 14 above indicates that in some cases, valve collapse can be
reversed by applying extreme pressure to the collapsed valve from the
flow layer. Collapse is seen in the left image and eventually removed, as
evidenced by the right image. Despite collapse, all chips were found to
function.
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3.

Chapter 3: C. elegans preparation and loading
3.1.

Introduction
In order to test the functionality of the microfluidic microinjection chip, a
synchronized population of C. elegans is necessary for testing. Worms must be at
the young adult stage (between L4 and adult) for successful microinjection of
genetic material12. These worms are then prepared and loaded into the
microfluidic chip at an acceptable concentration to ensure an even distribution
throughout the chip.

3.2.

Key constraints
Key constraints include:
1. maintaining a population of synchronized C. elegans hermaphrodites at
the young adult stage,
2. using the correct buffer solution (M9) to ensure that worms survive
moving through the microfluidic chip, and
3. loading the worms into the chip at an acceptable concentration to prevent
clogging.
3.2.1.

Constraint: Synchronized C. elegans population
A synchronized population of N2 hermaphrodites was needed for
microinjection to ensure:
(1) worms were the optimal stage for effective microinjection of
genetic material, and
(2) there was consistency of worm length and diameter for
optimizing chip dimensions.

12

Evans et al. “Transformation and microinjection.” WormBook, (2006).
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(1) For optimal microinjection and creation of a successful transformant,
worms must be healthy, young adult hermaphrodites with a limited
number of eggs13. See Figure 15 below for details regarding the relative
ages and reproductive stages if the C. elegans life cycle. At this age, the
worms are at the right reproductive stage for an injection to puncture and
flood the distal tip of the worm gonad with the desired genetic construct
(See Section 1.5: Figure 1 for more detail). This generates transformants
when the newly forming oocytes encapsulate the injected genetic material.

Figure 15. Life cycle of C. elegans. Life cycle schematic shows four larval stages of C.
elegans (L1-L4), the temporary, hibernative-like dauer stage, and the reproductive adult
stage. Time between life cycle stages at 23℃ is listed adjacent to transition arrows.
Diagram depicts relative sizes of each worm stage with young adults reaching a length of
1 mm and a width of 35-50µm. Reproductive adults are at the correct stage for
microinjection. Image from Wolkow et al (2015)14.

13

Evans et al. “Transformation and microinjection.” WormBook, (2006).

14

Wolkow et al. “Introduction to the Dauer Larva, Overview.” WormAtlas (2015).
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(2) Creation of a population of synchronized worms ensures that all
worms in the chip have relatively consistent dimensions. This consistency
is critical to optimize the microfluidic chip channel dimensions to allow
for: (i) smooth worm flow through channels, and (ii) effective worm
immobilization. For example, utilizing younger, and thus smaller, worms
like L1 larvae (see Figure 15) could prevent control valves from
effectively pinning down the worms for immobilization. The control
valves might also be unable to prevent worms from escaping under
actuated control valves. Additionally, older and larger worms might clog
the chip channels.
3.2.2.

Constraint: Maintaining C. elegans inside the chip
The worms must be suspended in a fluid to be loaded into the microfluidic
chip and pushed through the chip’s channels. In the lab, the worms are
generally grown on Nematode Growth Medium (NGM) agar plates
covered in a lawn of E. coli (OP50) bacteria15. The worms must be washed
off these plates and into an M9 buffer solution before they can be inserted
into the chip. Although the M9 solution does not contain a food source,
the worms can survive in solution for a few hours while the experiment is
in progress.

3.2.3.

Constraint: Loading worms at acceptable concentration
When preparing to load the chip for microinjection, the worms must be
washed off of their NGM agar plate and into a 1.5 ml tube. The number of
worms per plate is fairly consistent within each population, therefore it is
important to wash off the worms in the same amount of M9 buffer to
ensure a relatively consistent concentration of worms. If the concentration
of worms gets too high, the worms will flood the micropillar array and

15

Stiernagle et al. “Maintenance of C. elegans.” WormBook, (2006).
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clog the chip’s channels. See Figure 16 below for an example of an
acceptable worm concentration within the chip tubing.

Figure 16. C. elegans inside of microfluidic chip tubing. Worms are at the young adult
stage and are suspended in M9 buffer solution. Loaded into 200 µm diameter plastic tubing
for insertion into microfluidic inlet ports.

3.3.

Detailed design description
3.3.1.

C. elegans maintenance
For our experiments, we used a strain of wild type C. elegans worms
called N216 (see Appendix B for details), as they are a common strain that
is both easy to maintain and fairly robust for chip tests. They have a
generation time of roughly 3 days at room temperature (23℃) and a brood
size of around 350. Worms were grown at room temperature on Nematode
Growth Media (NGM) agar plates spread with a lawn of OP50 E. coli (See
Appendix C for NGM plate protocol details).

3.3.2.

C. elegans age synchronization
As stated in Section “3.2.1 Synchronizing C. elegans,” a synchronized
population on N2 hermaphrodite worms is needed for microinjection
because (1) it ensures consistency of worm length and diameter for

16

https://cgc.umn.edu/strain/N2
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optimal chip performance, and (2) worms must be at the young adult stage
for microinjection of genetic material to be effective. The worms were
synchronized using a hypochlorite solution procedure. The procedure
takes gravid N2 hermaphrodites and immerses them in a hypochlorite
solution to kill the adults while leaving behind the eggs (which are bleach
resistant). These eggs are allowed to hatch in media without food. Starved
L1 larvae will arrest until fed. Upon introduction of food, these larvae will
resume development from the same point, resulting in a synchronized
worm population. This process was repeated prior to each chip test to
ensure consistency of worm age and size. Waiting 3 days after
synchronization yielded worms at the desired young adult stage.
3.3.3.

Loading C. elegans into chip
When an NGM agar plate covered in young adult hermaphrodite worms is
ready for injection, the plate is washed with 1.0 mL of a worm-compatible
solution called M9 buffer (an anesthetic such as levamisole can be added
to M9 buffer if desired). Using the same 1.0 mL of fluid, the plate is rinsed
3-4 times before transferring the worm-containing solution into a 1.5 mL
centrifuge tube. To load the worms into the chip itself, the inlet tubing is
attached to a syringe and first filled with the worm-containing solution,
then loaded with pure M9 buffer. When the inlet tubing is connected to the
chip, this allows the pure M9 buffer to flush the channels before the
worms begin to enter.

3.4.

Results and discussion
For all chip tests, worms were maintained in large, synchronized populations.
Chip tests were conducted using young adult hermaphrodites. To load the worms
into the chip, they were washed off their NGM plates in M9 buffer, pulled into
microfluidic tubing using a syringe, and then inserted into the chip via its inlet
ports. Analogous to this loading procedure, the worms must be removed from the
chip post-injection. (See Appendix D for a subset of experiments that attempted to
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utilize a magnetic levitating cell-sorter by LevitasBio to sort living versus dead
worms exiting the chip outlet). Outlet tubing was allowed to drip M9 buffer +
worm solution freely onto NGM plates (without E. coli food source). The liquid
was allowed to dry before the live worms were picked and moved to a new NGM
plate with E. coli food.
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4.

Chapter 4: C. elegans Immobilization
4.1.

Introduction
Prior to microinjection, the worm must be properly immobilized. Failure to
properly immobilize the worm makes targeting the gonad nearly impossible.
Additionally, improper immobilization increases the probability that the
microinjection needle will tear and kill the worm. Thus, it is paramount that the
worm’s motion through the chip is highly controlled and that it is completely
immobilized for injection.

4.2.

Key constraints
4.2.1.

Cannot use negative pressure system controls
Our chip does not use negative pressure system controls. Most
microfluidic chips achieve microinjection through negative control
systems to immobilize worms. Negative control systems allow worms to
get sucked into smaller channels or get stuck against walls with gaps to
immobilize the worms. The microfluidic lab that we worked in did not
have these control systems. Therefore, in an effort to keep our project
accessible to as many labs as possible, we avoided using such systems.

4.2.2.

Only using positive pressure system controls
Positive pressure controls are the most widely available pressure control
systems in microfluidics. Our project therefore aims to achieve
immobilization using only positive pressure control valves. Enough
pressure on a control valve should be sufficient to immobilize a worm on
or against a microinjection needle17.

17

Ardeshiri et al. "A hybrid microfluidic device for on-demand orientation and multidirectional imaging of C.
elegans organs and neurons." Biomicrofluidics (2016).
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4.3.

Proposed analysis and expected results
4.3.1.

Immobilized worm motion measurements
Success of immobilization is frequently measured by examining how
much motion is seen in the worm. Measurements are frequently taken in
the x-axis (how much the worm moves left and right in the above image),
and the y-axis (how much the worm moves up and down in the above
image). Measurements magnitudes are taken in the micron scale.

4.3.2.

Anticipated results
Current chip design only immobilizes the mid-section of the worm, where
the gonad is located. The immobilization valve (2) is not the entire length
of the worm. We therefore expect to see significant movement around the
head and tail region of the worm, and hopefully very little movement in
the middle of the worm while it is pressed against the membrane.

4.4.

Back-up plan
Failure to immobilize will result in fewer successful transformants. If
immobilization fails, microinjection can still be performed, but the ability to hit
the gonad with a ~30% success rate will be diminished. As such, researchers will
spend more time attempting to get a successful injection, though even with a
reduced success rate throughput should still allow for more successful injections
per unit time than traditional methods.

4.5.

Materials and methods
The immobilization section of the chip has two main units, the left, upper, and
right control valves, and the flow channel and membrane of the fluid layer.
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Figure 17. AutoCAD schematic showing flow and control layer design in immobilization region. The red
numerically labeled features are in the control layer. The green alphabetically labeled features are in the flow layer.
The immobilization section has five main components: the left flow control valve (1), the upper immobilization valve
(2), the right flow control valve (3), the flow channel (A), and the microinjector membrane (B).

The rightmost valve (3) is pressurized so that liquid can flow past the valve, but
the worm cannot. Once a worm has reached this valve, the leftmost valve (1) is
sealed to prevent an additional worm from entering the area. The upper valve (2)
is then used to immobilize the worm by pressing it against the membrane (B). At
this point, the worm is at its most immobilized, and is ready for injection. After
injection, the upper immobilization valve (2) releases the worm from the
membrane, and the rightmost valve (3) releases to let the worm exit the chip. The
leftmost valve (1) is then opened again to allow for a new worm to enter the chip.
4.6.

Results
Figure 18 below shows an adult worm before and after actuation of the upper
immobilization valve. These results suggest that immobilization using positive
pressure is relatively successful—post-valve actuation, the worm’s body is
completely straight and pinned. The worm is incapable of any significant body
movement. However, immobilization using this method did show considerable
movement in the head (right) region of the worm. This method also showed that
the worm could be effectively immobilized between just two valves. In the above
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figure, the teeth are not functioning. As discussed in Section 2.6.2, improper
photolithography made the teeth shorter and failed to plasma bond.

2

2

3

A

A

B

B

Figure 18. Immobilization of C. elegans worms utilizing actuated control valve. (Left) Worm pre-immobilization
shown locked into microinjection region of chip. Control valves on either end of the worm (valves 1 and 3 are out of
view) are actuated to keep worm floating within microinjection region. (Right) Worm post-immobilization. Worm is
pressed against PDMS teeth (B) separating the worm flow channel from the microinjection region chamber. An
actuated control valve located directly on top of the worm (valve 2) is actuated to press the worm down and into the
teeth. Lower microinjector valve (See Section 2.3.4) also actuated. Numbers and letters correspond to AutoCAD
drawing shown in Figure 17.

4.7.

Discussion
Qualitative observations of immobilization suggest success regardless of teeth
presence. Immobilization was seen along the body of the worm, and not in areas
unaffected by valve actuation. Current observations are not conducive to
gathering quantitative data. Generating data about average movement ability is
made more difficult with the low resolution of microfluidic microscopes. Data
may be changed into qualitative movement data (did the worm move enough to be
seen or not), and then analyzed appropriately.
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1.

Chapter 5: Microfluidic Microinjection of C. elegans
5.1.

Introduction
To design a microfluidic microinjection device without external components, we
needed to develop a novel, on-chip microinjection apparatus. To do this we
embedded a portion of a microinjection needle into a PDMS membrane within the
chip (Figure 19) that could inject an immobilized worm within the chip’s flow
channel (Figure 19C). By filling the microinjection region with a genetic
construct and then pressurizing the chamber, the needle + membrane would
deflect into the worm and fluid would be injected into the worm. Additionally, by
pressurizing the control valve located directly above the worm, the worm would
be simultaneously immobilized against the thin membrane and pushed into the
fluid-ejecting needle. See Figure 19 below for the concept schematic of our novel,
on-chip microinjector.

Figure 19. Concept design for novel, on-chip microinjection chamber. (A) Embedded needle tip in membrane
separating microinjection region (filled with genetic construct) and worm channel. (B) Microinjection region
pressurized to deflect needle and expel fluid. (C) Schematic showing embedded needle alongside worm. (D) Actual
image of embedded needle tip.
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We were able to establish proof of concept for our novel microinjection chamber
by successfully injecting red dye into a worm.
5.2.

Key constraints
In order to create a novel, optimized microinjection apparatus, we needed to
address the following six constraints:
1. Needle tips must be pulled consistently.
2. Needle tips must be broken correctly and consistently prior to embedding.
3. Needles must be inserted deeply enough into the PDMS membrane to
ensure needle security but not so deeply that worms are accidentally
impaled in the flow channel.
4. PDMS membrane thickness must be optimized to ensure good needle
security and stability without compromising membrane deflection.
5. Pressure optimization in the microinjector chamber must ensure that the
correct volume of liquid (and eventually DNA reagent) is expelled from
the needle in the correct amount of time.
6. The immobilization valves must be able to hold the worm in place while
needle is deflected into the gonad.

5.3.

Detailed design description
5.3.1.

Needle preparation and insertion into membrane
5.3.1.1.

Pulling microneedles from glass capillaries
Two microneedles are pulled from one 1 mm diameter borosilicate
glass capillaries (Kwik-Fil Item#1B100F-4). Two microneedles are
made using the Flaming / Brown Micropipette Puller Model P-87
and the following parameters: Heat: 600, Pull: 40, Velocity: 55,
Time: 130, Pressure: 500. See below for image of Micropipette
Puller pulling 2 microinjection needles from a single capillary.
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Figure 20. Brown Micropipette Puller pulling two glass microinjection needles. (A) Heating element glowing
orange as it heats the glass borosilicate capillary pre-pull. (B) Post-pull microinjection needles.

To ensure that the needle tips are identical, the glass borosilicate
capillary must be carefully centered in the micropipette puller and
secured using the knobs shown in Figure 20 shown above. If done
correctly, one glass capillary will yield two virtually identical
microinjection needle tips. Note that glass pulling generally
produces needles whose tips are sealed or melted shut. The tips
must be broken before being used for microinjection.
5.3.1.2.

Breaking sealed needle tip
Sealed microneedle tips must be broken prior to insertion in the
chip or they will not be able to inject fluid into the worms.
1.

Place a drop of halocarbon oil on a glass microscope slide.

2.

Place a coverslip over the drop of oil and allow oil to
spread past the edge of the coverslip.

3.

Place prepared slide on microscope stage.

4.

Attach microneedle to micromanipulator.

5.

Drag needle tip along the edge of the coverslip until the
needle breaks. The user should see oil flow into the needle
tip. Alternatively, the needle can be preloaded with fluid
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and the user can test whether the needle is appropriately
broken by attempting to eject liquid (this is the method
utilized in standard, manual microinjection). This is shown
in below in Figure 21D.
6.

Remove needle from the micromanipulator and store.

See Figure 21 below for visual depiction of tip breaking procedure.

Figure 21. Breaking of glass microinjection tip to allow fluid flow. (A) Halocarbon oil drop on
glass slide. (B) Place coverslip over oil droplet. (C) Lightly drag the sealed glass needle tip against
the coverslip edge. (D) Barely break the needle tip to allow fluid flow.

5.3.1.3.

Cutting needle tip fragments for on-chip injection
Unsealed needle tips must be broken (see section 5.3.1.2 above) so
that embedded needle tips can eject liquid inside of the chip.
1.

Place 0.5” by 0.5” chunk of 5:1 (pre-polymer: crosslinker) fully
cured PDMS on a glass slide.

2.

Set freshly broken needle with tip resting on PDMS chunk and
tape down base-end of needle to slide (Figure 22 A, B).
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3.

Overlay 0.5” by 0.5” chunk of fully cured, 300 μm thick, 10:1
(pre-polymer: crosslinker) PDMS on top of the 5:1 PDMS
chunk. Gently tamp down 10:1 PDMS layer to ensure contact on
either side of needle tip (Figure 22 C).

4.

Cut microneedle tip to desired size using a razor blade. Cut
perpendicular to the needle all the way through both PDMS
layers to ensure needle fragment remains intact (Figure 22 D, E).

5.

Using tweezers, remove the top 10:1 layer of PDMS, checking
carefully to see which layer of PDMS the needle fragment has
adhered to. Move the PDMS chunk + needle fragment to a scope
with needle/micromanipulator attachment.

6.

Attach a fresh, unbroken “guide” needle to the
micromanipulator. Guide the fresh needle into the back of the
needle fragment to pick it up.

Figure 22. Cutting needle tip fragments used for on-chip microinjection. (A) Place freshly broken needle with tip
resting on 1:5 chunk of PDMS. (B-C) Tape down needle base and place thin (300um) layer of 10:1 PDMS on top of
needle tip. (D) Use a razor blade to manually cut straight down (perpendicular to the needle tip) through both PDMS
layers to break off desired needle tip length. (E-F) Separate PDMS chunks containing needle fragment, peel off 10:1
PDMS layer to reveal tip fragment, and insert fresh “guide” needle into base of needle fragment to pick it up.
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5.3.1.4.

Embedding needle fragments into membrane of microinjector
chamber
With the broken needle tip securely resting on the guide needle tip,
the guide needle can be used to bury the broken needle tip into the
PDMS membrane separating the microinjector chamber and the
worm flow channel (Figure 23). To do this, the PDMS chip (flow
+ control layer) must be placed upside down so that the needle pair
can reach inside the chip to the membrane of interest.
Once the needle tip has been embedded in the membrane, tension
must be placed on the tip so that the guide needle can slide out and
be removed. This is accomplished by laying a ~100 um protective
piece of 10:1 PDMS on top of the microinjector region and then
pressing down gently on the needle tip through the protective
PDMS. (Note: Without the protective PDMS layer, pressing on the
needle tip will either shatter the glass or slide the tip out of the
membrane.) While pressing down gently on the needle tip, the
guide needle can be retracted and then the protective PDMS layer
can be removed. Note that it is easier to slide out the guide needle
if you take care not to jam the guide needle into the broken tip
when you first pick it up. To finalize the chip, the PDMS chip +
embedded needle must be plasma bonded to a glass slide to seal
the microinjection chamber. See figure below for a visual
description of the needle embedding process.
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Figure 23. Embedding needle tip fragment into thin membrane of microinjector region. (Left) Schematic of
using “guide” needle to insert needle fragment into thin membrane. (Right) Top-down view of microinjector region
with embedded needle fragment after the guide needle has been retracted.

5.3.1.5.

Needle tip flow testing
With the needle tip firmly lodged in the membrane separating the
microinjection region and the worm’s flow channel, we needed to
test whether pressurizing the microinjection region would eject
fluid from the needle. Preliminary results showed that red food dye
can be successfully expelled through the needle at a pressure range
of 15-30 psi. Additionally, even at very high pressures, the dye was
ejected only through the needle tip and did not leak around the
base of the needle tip. See Figure 24 below to see ejection of red
food dye through the needle at 20 psi.

40

Figure 24. Ejection of red food dye through embedded microneedle tip. (Left) Image taken prior to pressurization
of the microinjection region. White area around needle indicates that the control valve located on top of the
microinjection region is actuated. (Right) Post-pressurization of the microinjection region at 20 psi. Control valve on
top of microinjection region is no longer deflected because of the equal pressure between the microinjection region
and control valve.

5.4.

Results
With needle tips firmly embedded in the microinjector membrane and proof that
liquid ejection was possible, we attempted preliminary microinjection attempts
with a synchronized worm population. Unfortunately, our worm population was
too old (worms had fully developed oocytes), however, we were able to
successfully inject 10 worms with red food dye using our novel microinjection
apparatus. See Figure 25 below to see the before and after of a successful
injection of an older adult worm.
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Figure 25. Injection of red dye into C. elegans using novel on-chip microinjector. (A) Pre-injection. Adult worm
trapped in microinjector region with valves on either side actuated. (B) Mid-Injection. Control valve located directly
on top of worm is actuated to immobilize and press worm into the fluid-ejecting needle tip. (C) Post-injection. Red
dye can be seen inside of worm body surrounding the developed oocytes.

To inject, we used the following procedure:
1. Load worm into microinjector chamber and trap it by actuating the control
valves located near its head and tail.
2. Test the microinjector by pressurizing the microinjection region until a red
plume appears beneath the worm.
3. While ejecting dye, actuate the control valve located on top of the worm in
the flow channel to immobilize and press the worm into the fluid-ejecting
needle tip.
4. While still ejecting fluid, de-pressurize the control valve that is
immobilizing the worm to allow the worm to slide off the needle.
5. As the worm slides off the needle, red dye seeps into its body, likely due
to the slight negative pressure created inside the worm during the injection
procedure.
5.5.

Discussion
Preliminary injection results are promising and serve as a proof of concept for our
novel, on-chip microinjector. However, the system we have designed is quite
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complex and it requires additional validation steps. Some of the aspects of our
design that require further optimization and analysis are:
(1) Pressurization of the microinjection region and how it affects membrane
deflection versus fluid ejection. By coupling the processes of needle
deflection and fluid ejection, we have created a mathematically complex
problem to solve.
(2) Actuation of the control valve located on top of the microinjection region.
It has the potential to alter the angle as well as the fluid-ejection capacity
of the needle that protrudes into the worm flow channel.
(3) Worm survival rate post-injection. We need to analyze how this
immobilization + compression-injection affects worm lifespan.
(4) Injection of actual genetic construct (not food dye) to generate successful
transformants.
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6.

Chapter 6: Chip Validation - COMSOL Simulation of
Microinjector Region
6.1.

Introduction
To predict whether the thin membrane + embedded microneedle would be able to
deflect enough to microinject and to visualize the effect of a pressurized valve on
embedded needle movement, we needed to conduct simulations using COMSOL.
COMSOL, a multiphysics software, uses finite element analysis to provide a
model and simulation system. To obtain a range of membrane deflection values,
the microinjection region was modeled in COMSOL. In COMSOL, parameters
such as pressure and membrane thickness, can be swept over a range to predict
the resultant deflection outputs. Then, in order to visualize the embedded needle
movement, a side-view cross section of the chip was modeled in COMSOL.
Varying the pressure of surrounding chambers can provide valuable insight as to
how the needle will react when we pressurize the chambers in our chip.

6.2.

Key constraints
The membrane deflection range and behavior of the embedded needle are
constrained to the multiphysics software of COMSOL. While COMSOL provides
the tools to model the deflections associated with the microinjection region of the
chip and the pressurized chambers effect on the movement of an embedded
needle, it is only a theoretical simulation. The physical microinjection chamber
and embedded needle will not necessarily behave according to the ideal
conditions of the simulation. Additionally, the movements and reactions of C.
elegans animals are not fully predictable.

6.3.

Detailed design description
6.3.1.

Microinjection region for membrane deflection simulation
The microinjection region of the chip can be modeled simply by using an
assortment of blocks with dimensions matching the chip. The model, as
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seen in Figure 26, consists of six total blocks to create a glass base, walls
surrounding an open chamber, and a thin membrane to top the chamber. In
the physical chip, however, there is no glass base backing the chamber, so
the sturdy properties of glass are used to mimic the thick PDMS base
relative to the thin membrane.

Figure 26. COMSOL model of microfluidic microinjection region based on a glass model.
The fully constructed COMSOL model of the microinjection region for our chip. The top-most
surface is the thin membrane between the microinjection chamber and the worm flow channel.

COMSOL allows model parts to be hidden to show interior structures.
Figure 27 shows the highlighted chamber once the glass base has been
hidden.

Figure 27. COMSOL model of microinjection region chamber. Inner chamber of the
microinjection region after the glass had been “hidden” in COMSOL and the chamber surfaces had
been selected.
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To simulate the bonded nature of the chip, once created, the blocks were
mated. This mating was important to simulate the fully bonded chip. The
model now functions as a single unit. To distinguish the glass base from
the PDMS, materials were assigned to blocks. The PDMS has a Young’s
modulus of 1000 kPa, a Poisson’s ratio equal to 0.49, and a density of
1000 kg/m3. The glass only increases in the Young’s modulus value from
1000 kPa to 1000 MPa.
6.3.2.

Embedded needle for needle movement simulation
To simplify the model of needle movement, COMSOL was used to model
the side-view cross-section of the chip. As shown in Figure 28, the model
uses an assortment of rectangles that resemble the chip dimensions.

Figure 28. COMSOL model showing effect of control valve on embedded
needle movement. Two-dimensional model of the chip used for studying the
movement of the needle embedded in the thin membrane.

Similar to the microinjection region, these rectangles were mated to mimic
the bonding of the layers. Then, assigning materials helps to distinguish
the rectangles so that each contributes to a model that more closely
resembles the true nature of the chip. Using the same material properties
for the glass and PDMS materials as the three-dimensional microinjection
chamber model, the base rectangle and the thin rectangle, that appears to
be a line through another rectangle, are glass. The base rectangle is the
glass base, and the thin rectangle represents the embedded needle. The
remaining rectangles are PDMS.
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6.4.

Simulation methods
6.4.1.

Membrane deflection simulation
Deflection values for the membrane were obtained while varying the
chamber pressure and the membrane thickness. COMSOL contains a
function called “parametric sweep” that computes simulations for a range
of desired values. To use this function, the variables or parameters must
first be defined. Under the global definitions, we defined pressure and
membrane thickness as parameters. Then, the set value for these
parameters must be changed to the parameter name. Once set up, we
computed the parametric sweep then we evaluated the results for
maximum deflection. This was done for three models with differing
membrane thicknesses—1 µm, 50 µm, and 1000 µm.

6.4.2.

Needle movement simulation
The needle movement simulation is more ambiguous. In theory, the
microinjection chamber and the valve above this chamber will be
pressurized over a range of pressure inputs to study the reaction of the
needle. However, because COMSOL is a multi-physics simulation
software, certain interactions must be more explicitly defined. At high
enough pressures in the top chamber, deflection of the membrane will
touch the needle. This interaction is not defined in COMSOL. Yet,
COMSOL contains a function called “contact pairing” that can resolve the
interaction problem between the membrane and the needle. Once the
surfaces are paired, then the pressure values can be swept to evaluate the
needle movement.

6.5.

Results and discussion
6.5.1.

Membrane deflection
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When we computed the parametric sweep that simulated the pressurization
of the microinjection chamber, we saw clear deflection across the thin
membrane. This deflection simulation is pictured in Figure 29.

Figure 29. COMSOL model depicting the membrane stress that results from applying a boundary load to
microinjection chamber. The dark blue areas of the model are not stressed. The light blue and orange areas show
stress and deflection of the thin membrane. The orange indicates increased stress, revealing maximal stress located in
the center of the thin membrane

Once deflection was observed in the model, the simulation was evaluated
for maximal membrane deflection. For the three different models with
varying membrane thickness, the maximal deflection was plotted against
the input boundary load as shown in Figure 30.

Figure 30. Graph comparing applied pressure to thin membrane deflection based on COMSOL simulation. The
maximal deflection of the thin membrane is computed and graphed according to the pressure of the chamber. This was
computed for models with membranes of varying thickness—1 µm, 50 µm, and 1000 µm.
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These results gave valuable insight to our observations as we pressurized
the microinjection region of our chip. Because the source of the behavior
of the membrane was unclear, isolating the deflection without liquid
ejection in a simulation allowed us to see the deflection of the membrane
only as a product of pressurization with no confounding variables.
6.5.2.

Needle movement
Due to the complexity of simulating the movement of the needle, this is an
ongoing simulation project. Ideally, these results will give us greater
insight as to how the pressurization of these chambers affects the behavior
of the needle in the membrane.

6.5.3.

Discrepancies between simulation and observation
The results of the simulation are not similar to observations of the system.
Upon pressurizing the microinjection chamber, very little to no deflection
is seen, in contrast to the approximately 20 micron deflection that is
expected, this is likely because this simulation is coupled with a fluid
ejection model, and the two systems have not been reconciled. Future
work will need to create a system with both of these elements.
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7.

Chapter 7: Summary and Conclusion
7.1.

Restatement of project objective
Our objective was to design a microfluidic device that could conduct on-chip
immobilization and microinjection of C. elegans without the aid of any external
elements. Our chip aimed to increase microinjection efficiency, consistency, and
accessibility to researchers of all experience levels in order to advance genetics
research and genetic engineering technology in C. elegans.

7.2.

Project accomplishments
7.2.1.

100% microfluidic device
Our final device is completely microfluidic. There are no external
components beyond those required to operate a microfluidic device. Our
chip can be operated using multiple microscopes such as a basic dissecting
scope (not just an inverted). The compatibility of our chip allows for
future full automation via computer vision and programming. Overall, our
chip is cheap, and easy to use regardless of your experience level.

7.2.2.

Design novelty
Our chip novelty is the on-chip microinjection apparatus. Without
cumbersome external elements, our chip is easier to setup and use.
Additionally, our chip has the potential to unclog clogged needle tips. If
the worm flow channel is pressurized, fluid is forced backward through
the needle, expelling clogging debris. The ability to unclog needles saves
researchers from wasting valuable time and reagents.
Another novel aspect of our design is its brief worm-immobilization time.
Compared to other chips and methods, our design immobilizes worms for
a fraction of the time, reducing unnecessary strain on the worm’s body.
Worms spend a maximum of 1 second immobilized before being allowed
to float off the needle and into the channel again. By reducing the total
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stress exerted on the worm, we increase the likelihood of their survival.
This increases the number of successful injections and ensures that
valuable worm strains are not wasted.
7.3.

Future work
7.3.1.

Complete characterization of novel, on-chip microinjector
The physical properties of the novel, on-chip microinjection apparatus is
not yet fully understood. Currently, our design utilizes two integrated
systems, (1) a physical deformation system, and (2) a fluid ejection
system. This poses a challenging math and physics problem as the
relationship between chamber pressurization is confounded with both
membrane deflection and fluid ejection. We are currently conducting
ejection rate experiments to characterize the needle tips. We are also
exploring further COMSOL simulations to try to better understand the
discrepancy between our COMSOL simulation results (see Chapter 6) and
our failure to observe membrane deflection in our experiments.
In addition to the issue of the coupled deflection-ejection system, we need
to fully characterize the effect of actuation of the control valve located
directly above the microinjection chamber (see Figure 7, red valve below
valve 2) on the angle of the needle. It is unclear how dramatically the
valve actuation affects needle angle and whether it has the ability to fully
stop needle fluid flow when actuated.

7.3.2.

Injection of genetic construct
Currently, we have been injecting red food dye into the worms to better
visualize the injection process. Moving forward, we will be injecting a
clear solution containing our genetic construct. We will be injecting a
plasmid (rol-6[su1006]) that confers a “roller” phenotype to the worms.
This means that we will be able to determine transformation efficiency by
scoring the number of “roller” worms generated by our injections.
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7.3.3.

Post-injection analysis
Finally, to evaluate the effectiveness of our chip as a tool for C. elegans
microinjection, we will need to determine (1) transformation efficiency,
(2) the rate at which worms survive the injection procedure, and (3), the
effect of our injection technique on worm lifespan. All three of these
statistics will be obtained once we start regularly injecting synchronized
populations of young adult worms with our rol-6 plasmid.

7.4.

Engineering standards
This project addresses multiple engineering concerns: ethics; health and safety;
manufacturability; usability; science, technology, and society; economic;
environmental impact; civic engagement; and sustainability. The ethics of this
project will be examined throughout each subsequent engineering standard. For a
more thorough and ethics-specific analysis, see Appendix E.
7.4.1.

Health and safety
All users have a right to their own safety and a similar duty to maintain
their own and the safety of others. Our product both introduces and
mitigates risks in comparison to traditional microinjection. While
mitigation of existing risks is beneficial to all, the introduction of some
new risks may outweigh whatever mitigation is introduced. The danger
that any of these risks pose is entirely based on user expertise and
experience.
The majority of the new risks that we introduce are the result of the
additional facilities and equipment that our project requires for fabrication
(See Section 3.1). Our project calls for the use of chemicals that are
known to be hazardous (toxic, flammable), and uses a machine that
requires UV light. Exposure to chemicals can be mitigated by wearing
proper protective equipment (PPE) and following lab safety protocols, and
eyes can be protected from UV exposure. However, other exposed areas of
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the skin (mouth, neck, etc.), cannot be protected from the UV light, and it
is recommended that the user face away from the machine during
exposure times.
Our product fabrication also requires that some microinjection equipment
be used in untraditional ways. The micromanipulator and inverted
microscope are used to break micron scale glass needle tips from
traditional microinjection needles. While protocols have been created to
diminish the risks and handling of these micron size needle fragments,
always consult with the owner of the equipment before using it as our
product requires. PPE should always be worn to avoid fragment contact
with the skin, and eyewear is essential to avoid getting fragments in the
user’s eyes.
No injuries have occurred over the course of this project while completing
any procedures. Despite the risks introduced, current safety protocols in
most lab spaces should be sufficient to mitigate risks and potential harm.
Overall, the biggest potential risk to a user’s safety is introduced by the
user alone if she chooses not to follow appropriate PPE guidelines and
safety training.
Our product eliminates multiple dangerous elements required by
traditional microinjection. It no longer requires the user to directly interact
with glass with molten sections, and our product decreases the need for
exposed flames in lab. Our product eliminates the requirement of mouthpipetting to load genetic material into microinjection needles. While most
of these genetic materials have little immediate risk to a user’s health,
mouth pipetting should always be avoided. Our product also reduces the
probability that a user impales their hand on a needle when loading genetic
material into a microinjection needle.
Traditional methods have higher hazard risk than our final solution. Our
solution introduces new hazards with known safety procedures. Our
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solution does not require that any used chemicals come into even remote
contact with the mouth. Traditional microinjection also has a high
probability of physical injury, via either puncture wounds or burns. It is
hard to mitigate the probability of these risks, as they are necessarily
introduced for the sake of traditional microinjection.
7.4.2.

Manufacturability
Our product requires multiple facilities and a variety of equipment:
research location determines feasibility of use. If one is already capable of
conducting C. elegans microinjections, the individual would still require a
significant amount of resources to be capable of using our product.
The microfluidics side of our product requires a cleanroom, a microfluidic
laboratory, and lots of equipment (spin coaters, a mask aligner, volatile
chemicals, etc.). The product also requires a microfluidic multiplexer,
multiple air and vacuum sources, and the accompanying software to make
the multiplexer work.
Santa Clara University is fortunate to already have all of these facilities
and materials, no new equipment was purchased to make our device work.
If a C. elegans researcher find themselves in a similar position, then our
product will work for them. Current prototypes are capable of injecting
over twelve worms per use, compared to three injections for traditional
methods. Our chip also has the unique ability to unclog its needles, saving
more genetic reagent in comparison to traditional methods. Finally, our
product can be used under any microscope, freeing microinjection from
the inverted microscope. Our product saves time, allowing for more
injections, more experiments, and more research.
However, while other facilities and universities have access to the required
spaces, many C. elegans researchers do not. This is a violation of fairness;
our product can only be used in higher-end research settings. Deciding
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reparations for this violation is difficult, the common-good approach
would imply that those with access to our product have a duty to share
their findings to those without access. In the C. elegans research
community, people are much more forthcoming with their findings, but
our product does not diminish the barrier between C. elegans researchers
with access to higher-end facilities versus those with access to lower-end
facilities. It is possible that our product could be commercially built, but
then it would still require a microfluidic multiplexer and software to
function, neither of which are cheap.
7.4.3.

Usability
As mentioned in Section 1.2, microinjection is a linchpin to C. elegans
genetics research. Assuming a researcher can access and use our product,
she will find this is no longer the case: microinjections can be performed
by anyone with our product, and they can be performed quickly. Hence,
we anticipate more publications pertaining to C. elegans and
microinjection, potentially to the chagrin of established microinjection
researchers. Overall, though, our product long term benefits outweigh its
immediate consequences.
Our product requires one person for complete fabrication. It does not
require someone with a doctorate, but fabrication of the product relies on
someone having basic knowledge about microfluidics. Hence, the
knowledge required to complete microinjection is less severe, but may not
be found in a traditional C. elegans research laboratory.
Our product requires two people to operate. Operation of this device is
very difficult without two people, primarily due to the software that
interacts with our chip. On a per capita basis, our product requires more
than traditional methods; however, it also increases opportunities for a
workforce of undergraduate research students looking for work in labs.
Allowing undergraduates to participate in the research and assist in
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operations would also afford the PI more time to examine topics that are
less familiar to other students. In general, despite the increase in
personnel, the project as a whole is more accessible to everyone; allowing
for better division of labor and more rapid progress.
7.4.4.

Science, technology, and society
Our product is designed to support research in the field of genetic
engineering, particularly within C. elegans. C. elegans is studied due to
the high amount of overlap between their genome and humans. Ultimately,
researchers hope to apply their findings to humans. Genetic engineering in
humans is a controversial topic: it holds the potential to cure many
diseases, but at the most extreme of ends could result in the creation of
“designer babies.” Our product has the potential to bring about either one
of these ends - society and genetic engineers will have to choose which
ones we achieve. In order to reach the most desirable of ends, it is
essential that we continue to talk about genetic engineering, its potential
impacts, and how we wish to use the technology. This is the best way to
ensure that our product does not help realize an undesirable future.

7.4.5.

Economic
The cost of our product is low. Based on raw materials alone, an
individual chip costs no more than five dollars (PDMS, C. elegans
maintenance supplies, etc.). It is difficult to account for the costs that our
equipment incurs, though. We are fortunate in that no additional
equipment needed to be purchased for our project. The most expensive of
items (inverted microscope, mask aligner, micromanipulator, clean room)
already existed on SCU’s campus. If we were to secure our own facilities,
costs for our product would go up exponentially. Finally, as students, we
do not charge for labor. In total, about ten hours are required to make a
chip from scratch (no mold), if a mold is present, six hours are required
(mold casting and needle embedding). Lots of this labor requires skilled
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technicians and would drastically increase the cost of our chip. For our
purposes, our chip is cheap - this may not be the case outside of SCU.
7.4.6.

Environmental impact
Our product has two primary wastes: sharps and chemicals. Sharps are
convenient enough to dispose of, our chemical waste is another story. All
chemicals pertaining to mold fabrication (See Section 2.5) are hazardous
(toxic, flammable), and require care to be disposed of properly. PDMS
becomes far less toxic as it cures, eventually becoming biocompatible.
However, chip fabrication wastes a lot of PDMS. While we have
attempted to mitigate PDMS waste throughout our project (some is reused
for the needle cutting procedure), there is still inevitable waste, which
must be taken into consideration.

7.4.7.

Civic engagement
There is potential for a patent in our product. Approval for a patent will
need to be filed through the US patent office. In order to receive a patent,
we will need to prove that our product does not infringe upon any other
patents. Similarly, we will need to prove that our product is novel enough
to warrant receiving its own patent.

7.4.8.

Sustainability
Our product is more sustainable than traditional methods, though
microfluidic chips are inherently disposable. Needles clog frequently in
microinjection due to their small size, but our chip does allow them to be
unclogged. Therefore, we can get needles to last longer than usual. Chips
should not be used for multiple genetic constructs, as microinjection
chambers are nearly impossible to wash out.
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7.5.

Team and management
For more detailed information related to our project, see Table 1 below for
relevant contact information.

Table 1. Team member specialties and contact information.
Name

Email

Discipline

Project Expertise

Delaney Gray

drgray@scu.edu

Bioengineering

C. elegans, needle embedding,
microfluidics/fabrication

Alex Hadsell

ahadsell@scu.edu

Bioengineering

Microfluidics/fabrication, AutoCAD, stats

Jessica Talamantes

jtalamantes@scu.edu

Bioengineering

COMSOL simulations, LeviCell

Advisor

Dr. Emre Araci

iaraci@scu.edu

Bioengineering

Microfluidics, microfabrication

Advisor

Dr. Leilani Miller

lmiller@scu.edu

Biology

C. elegans, manual microinjection

Team

7.6.

Budget
For general budget information, see Table 2 below. All funds were provided by
the Santa Clara University School of Engineering. All supplies not listed were
generously provided by Dr. Emre Araci (SCU Bioengineering Department) and
Dr. Leilani Miller (SCU Biology Department).

Table 2. Project budget breakdown.
Category

Item

Number

Unit Cost ($)

Total ($)

Silicon wafers (10 cm)

10 wafers

10.00

100.00

SU-8 2050

1 (500 mL)

650.00

650.00

1 (4L)

172.90

172.89

SPR

1 (500 mL)

700.00

700.00

SPR Developer

1 (1 gallon)

48.75

48.75

PDMS

1 gallon

700.00

700.00

TMCS

50 ml

120.00

120.00

Bactopeptone

1 (500g)

133.57

133.57

Agar

1 (500g)

181.98

181.98

60 mm worm plates

1 case (500)

52.97

52.97

Glass capillaries

1 box (500)

57.00

57.00

Photolithography supplies SU-8 Developer

Soft lithography supplies

C. Elegans supplies

Total cost: $2,917.16
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7.7.
8.

Project timeline

Our project was broken down in four main phases which loosely corresponded to the four
quarters we spent working on this project. We spent the Spring (2018) of junior year
conducting background research on our project and formulating our initial microfluidic
chip design. The following three quarters in our senior year were spent designing,
manufacturing, and testing three different iterations of our chip design. For a general
overview of our project timeline, see Table 3 below.

Table 3. Project timeline.
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1.

Appendices

2.

Appendix A: Manual microinjection procedure

Figure 31. Schematic of manual microinjection procedure. (A) Glass slide (light blue) with agarose
injection pad (gray). (B) Drop of halocarbon oil (yellow) placed on injection pad to act as temporary buffer
between worm and sticky injection pad. (C-D) Worm manually placed in oil droplet for maneuvering. (E)
Worm is manually oriented using a modified (heat-blunted) glass Pasteur pipette. Worm is rolled until gonad
is in proper position for a successful injection. (G) Once aligned, worm is pressed down through the oil to
contact the adhesive injection pad. (F) With worm securely adhered, a microinjection needle can be brought
alongside the worm and the worm is injected. See Evans et al (2006) for detailed instructions regarding
manual microinjection1.

1

Evans et al. “Transformation and microinjection.” WormBook, (2006).
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3.

Appendix B: Ordering and maintaining C. elegans N2 strain

4.

C. elegans strains can be ordered from the Caenorhabditis Genetics Center2. The C.
elegans wild isolate N2 strain was utilized for all chip experiments. C. elegans animals
are hermaphroditic (although males arise at a rate of < 0.2%) and can self-fertilize a
brood size of about 3503. Their generation time is temperature-dependent; At 23℃, their
generation time is about 3 days from egg to egg-laying adult. At 20℃, their generation
time is about 4 days. At 15℃, their generation time is about 7 days. The N2, wild type
worms used in these experiments were maintained at 23℃ and allowed to self-fertilize.

5.

Appendix C: Preparation of Nematode Growth Medium (NGM) agar plates

6.

Materials
● 60 mm non-vented sharp edge petri dishes4
● PourBoy Sterile Media Dispenser5
● Magnetic stir bar
● Magnetic stir plate
● 2L Erlenmeyer flask
● Aluminum Foil
● Autoclave tape
● Deionized water (Barnstead 10 megaohm)
● NaCl salt
● Bacteriological Grade Agar6
● BD Bacto™ Peptone7
● 5 mg/ml cholesterol in ethanol
● 1 M CaCl2
● 1 M KPO4
● 1M MgSO4

2

https://cgc.umn.edu/
Corsi et al. "A transparent window into biology: a primer on Caenorhabditis elegans." Genetics, (2015).
4
http://www.tritechresearch.com/petri.html
5
http://www.tritechresearch.com/pourboy.html
6
https://catalog.hardydiagnostics.com/cp_prod/product/c5001-agar-bacteriological-grade-criteriondehydrated-culture-media-500gm-wide-mouth-bottle-by-hardy-diagnostics-dehydrated-media---criterion
7
https://us.vwr.com/store/product/16078369/bd-bacto-peptone-bd-biosciences
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● Cholesterol (5mg/ml)
Methods
▪

•

1450 ml diH2O (Barnstead 10 megaohm)

•

30g Bacteriological Grade Agar

•

3.75g BD Bacto™ Peptone

•

4.5g NaCl salt

▪

Mix with magnetic stir bar.

▪

Cover mouth of flask with foil, mark with autoclave tape, autoclave on liquid
cycle (20 minutes).

▪

Autoclave PourBoy tubing on gravity cycle (10 minutes).

▪

Place media flask into 65 centigrade water bath and allow to cool for 1 hour.

▪

While cooling, prepare plate pouring workspace:

▪

▪

▪

In the 2L Erlenmeyer flask combine:

•

Clean counters with lysol.

•

1 flask of media should fill 6-7 sleeves of petri dishes (20 per sleeve). Set
up petri dishes in stacks of 5.

•

Set up PourBoy sterile media dispenser and spray ethanol on the bracket
area to sterilize.

•

Set PourBoy to dispense 11-12ml of media per plate.

Once cooled, add the following salts in order to the autoclaved media:
•

1.5ml 1 M CaCl2

•

1.5ml 1M MgSO4

•

37.5ml 1 M KPO4

•

1ml Cholesterol (5mg/ml)

Pouring NGM agar plates:
•

Run one bottle of 50/50 autoclaved diH2O followed by one bottle of
autoclaved diH2O through the pump system.

•

Carefully place tube into media flask and pump until air bubbles clear and
NGM agar is flowing smoothly.

•

Pour 11-12 ml of NGM agar into each plate (one pump per plate).

•

Once done, immediately rinse 2L flask and PourBoy tubing with hot water
to prevent solidification of agar inside.

Allow NGM agar plates to dry for 3-4 days before spreading.
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▪

Spreading NGM agar plates with E. coli OP50 bacteria food source

•

C. elegans animals are generally maintained monoxenically with an E. coli (OP50) bacterial food
source. E. coli OP50 is an uracil auxotroph that is growth-restricted by the lack of uracil found in
NGM agar plate media8. It is spread manually on NGM agar plates and grown as a restricted
lawn.

Appendix D: Magnetic density-based sorting of C. elegans
Introduction
LevitasBio, a local bioengineering company in the Bay Area, created a “Magnetic
Levitation Technology,” and implemented this novel technology into their device,
LeviCell. LeviCell consists of two permanent magnets on either side of a flow
channel. Previously, this device has been used for cell analysis and sorting. When
cells flow through the channel, the magnet technology generates separation,
provoking the cells to levitate based on cell type. This observable separation is
dependent primarily on cell density and is supplemented by the magnetic
properties of the cells. Further separation occurs as the sample flows into a
bifurcated tube, allowing for collection of the separated samples. The device
allows for flow control so, in addition to controlling flow rate, the sample in the
channel can be held for levitation analysis.
One of our senior design advisors, Dr. Emre Araci, had been in contact with
LevitasBio about installing LeviCell on Santa Clara University campus and
potential research opportunities with the technology. With the novel separation
technology, we were curious of the potential application in C. elegans sorting—
whether that is sorting worms of different sizes, sorting live worms versus dead
worms, or some other type of sorting—, rather than cell sorting.

8

Stiernagle et al. “Maintenance of C. elegans.” WormBook, (2006).
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Detailed design description
With no prior C. elegans exploration in LeviCell, we approached the technology
from a discovery-based standpoint. We were interested in whether the levitation
technology would affect C. elegans worms.
LeviCell viability
The LeviCell technology does not rely solely on the permanent magnets
surrounding the flow channel. Instead, the sample of interest must be
suspended in a levitation reagent. So, we decided to first test whether the
C. elegans worms tolerate the reagent. We created two solutions, the first
using DI water. DI water is commonly used as a buffer solution when
using LeviCell. However, DI water is known to aggravate C. elegans
worms. So, we made the other solution using the known worm-compatible
buffer, M9. Diluting the levitation reagent to a 1X concentration, we
suspended the C. elegans worms and observed the worms over increments
of a two-hour time period to assess viability.
Preliminary Tests
Once we proved that the Levitas levitation reagent was not toxic for C.
elegans, we decided to observe how the LeviCell device affected the
worms. A few plates of live C. elegans were washed using the M9 buffer,
and this worm solution was then combined with the levitation reagent to
create a 1X concentration just as in the viability test. Then, after properly
preparing and priming the LeviCell device, the sample of worms was
flowed through the device.
Control Tests
After confirming that the LeviCell device affects C. elegans worms, the
question became whether there were noticeable levitation differences
between any variation of the worms. For this reason, the worm samples for
the control tests were more precise. We prepared three worm samples in a
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1X concentration solution of levitation reagent and M9 buffer. The first
sample was a live sample, similar to those from the preliminary tests. The
second sample consisted of anesthetized worms. The worms were
anesthetized using the same methods described in Chapter 3 of this paper.
For the third and final sample, the worms were killed in bleach. This
process followed the same bleaching process used in the worm
synchronization described in Chapter 3. Then, after preparing and priming
the LeviCell device, each sample was again flowed through the device.
Expected Results
While cells are relatively small and immobile, adult C. elegans used for genetics
research are approximately 1 millimeter in length and 40 𝜇m at their largest
diameter—significantly larger than individual cells. In addition to their size, C.
elegans animals are extremely mobile and tend to swim against the current of the
flow. Due to these characteristic differences, we were not sure what to expect
when introducing C. elegans to LeviCell. We were expecting the magnetic
levitation technology to affect the C. elegans, but we were not sure to what extent.
Additionally, the densities of C. elegans worms are unknown, and thus, there was
a potential for variations in levitation height resulting from any number of
variables. We considered age as a potential factor. Whether or not the worms
were alive, dead, or anesthetized was another potential factor. Ultimately,
however, we did not anticipate significant levitation height differences as there
does not appear to be a significant difference in worm densities considering the
controlled variables.
•

Materials and Methods
o Materials
▪

Maintained C. elegans plates

▪

M9 Buffer

▪

Materials for anesthetizing and bleaching the worms

▪

20X Levitation Reagent
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o Preparing the Live Sample
▪

Wash the worm plate using 1 mL M9.

▪

Transfer 50 µL 20X Levitation reagent into a clean, labeled 1.5 mL
centrifuge tube.

▪

Transfer all the M9 solution containing the C. elegans worms into the
same tube and add M9 until the total volume is 1 mL (some M9 was lost
while washing the plate).

o Preparing the Anesthetized Sample
▪

Follow the method for anesthetizing the C. elegans

▪

Transfer 50 µL 20X Levitation reagent into a clean, labeled 1.5 mL
centrifuge tube.

▪

Transfer the C. elegans solution to the same tube.

▪

Add M9 until the total volume is 1 mL.

o Preparing the Dead Sample
▪

Follow the method for synchronizing the worms.

▪

Resuspend the dead worms in 0.5 mL M9.

▪

Transfer 50 µL 20X Levitation reagent into a clean, labeled 1.5 mL
centrifuge tube.

▪

Transfer the resuspended C. elegans to the same tube.

▪

Add M9 until the total volume is 1 mL.

Results
The initial viability tests revealed that the levitation buffer is not toxic to C.
elegans. Additionally, those initial tests confirmed the well-established
knowledge that a C. elegans prefers M9 buffer to water.
The preliminary attempt to insert a live, unanesthetized sample into the LeviCell
device showed that the magnetic levitation technology does, in fact, affect C.
elegans. As shown in Figure 32, the C. elegans animals are seen levitating in a
confined band within the flow channel of the LeviCell device. With this
preliminary test, there was no clear pattern to the outliers. There were occasional
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eggs flowing outside the band, and there were occasional C. elegans, either
developing or developed, that were not constrained to the band pictured in the
figure. However, the live C. elegans were seen beyond the band more frequently
than the eggs.

Figure 32. Live, unanesthetized worms levitating in LeviCell instrument. The agar plate washed
for this experiment was not synchronized, thus providing the observable age variety from eggs to
adults.

The control tests featured the three sample environments—live, unanesthetized C.
elegans, live, anesthetized C. elegans, and dead worms. The live, unanesthetized
sample did not deviate from the preliminary test. The live, anesthetized sample,
seen in Figure 33, showed a similar result. Eggs and anesthetized worms alike
flowed through the channel in a relatively confined band. The outliers appeared
less frequently compared to the unanesthetized sample, yet, there were still
occasional outliers. Notably, the live, anesthetized C. elegans sample band
appeared to levitate at a lower channel height.
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Figure 33. Live, anesthetized worms levitating in LeviCell instrument.

Not surprisingly, the final test, featuring the sample of dead C. elegans showed
minimal results. Due to the rapid decay of the C. elegans’ organism following a
bleach treatment, the sample did not contain enough matter for observation.
Discussion
Because there is minimal research relating LeviCell use and C. elegans, there are
many potential avenues for future research. It is known that varying the levitation
reagent can increase the separation between matters of different densities.
Additionally, it would be interesting to test the effect of injection on the levitation
height, and the crossover of the magnetic levitation technology and C. elegans
needs to be explored. Therefore, because we have proven that the technology
affects the organism, there is enormous capacity for future research.
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Appendix E: Ethical Analysis of Microfluidic Chip for Microinjection of C. Elegans
1.

Introduction
For our Senior Design Project, we designed a microfluidic device to perform
microinjection of genetic material into C. elegans, an invaluable model organism. Our
project objective was to increase microinjection efficiency, consistency, and accessibility
to researchers of all experience levels in order to advance genetics research and genetic
engineering technology in C. elegans.
1.1

Caenorhabditis elegans is an invaluable model organism
C. elegans is a terrestrial soil nematode that has served as a model system for
human disease and genetics research since the 1970’s. The worm is an invaluable
model organism for the study of molecular and cellular processes in humans due
to their small size, rapid generation time, easy cultivation, and invariant cell
number. Additionally, 40% of genes known to be associated with human disease
have clear orthologs in the C. elegans genome.

1.2

Limitations of traditional microinjection methods
In C. elegans genetics research, microinjection of genetic material into the worms
is critical. Although an established technique, manual microinjection is tedious,
error-prone, low-throughput, and requires an expert researcher. From start to
finish, the process takes about four hours and can result in many failed injections
even with an experienced researcher. As a result, microinjection has a bottleneck
effect on genetics research in C. elegans, greatly restricting the field.

2.

Primary Ethical Considerations of Project
Our project has three primary ethical concerns all related to accessibility: whether our
solution is indeed more accessible than traditional microinjections, how we might be
negatively impacting the researchers that can already perform microinjections, how
increased accessibility may result in abuse of our product and the science around it, and
the product’s overall safety.
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2.1

Accessibility of our solution
If our final solution is more complicated than existing technologies, then it’s
worth must be called into question. If our project replaces the need for someone
with a doctorate in genetics with someone with a doctorate in microfluidics, then
we have not made microinjections more accessible.

2.2

Consequences of making research more accessible
If our product is accessible to a researcher, they will find that C. elegans genetics
research is also more accessible. Our project may deprive some C. elegans
researchers that are capable of microinjection from future papers. In academia,
success is frequently measured by an author’s publications. Current researchers
may find that papers they planned on researching will now be addressed sooner
by other labs.

2.3

Potential abuse of our product as a result of accessibility
Along with increased accessibility will come increased use. As with any product,
it is essential to consider how this product could be misused, particularly in the
laboratory setting.

2.5

Safety
It is important to consider all safety concerns that our product contains. Our
product uses a variety of facilities and chemicals that are hazardous to one’s
health. Some portions of the project also contain physical hazards.

2.4

The ethics of genetic engineering
The field of genetic engineering is full of ethical questions that merit entire
essays, these questions are not the focus of our ethical discussion. While genetic
engineering is surely a consideration of our project, we intend to focus on the
accessibility of a technology primarily and acknowledge that many discussions
must continue to be had about the ethics of genetic engineering in general. Failure
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to consider the long-term consequences of our technology is of course
problematic, but for brevity and to avoid the sometimes-infinite consequences of
our decisions, this discussion must be omitted from this paper.
3.

Is our product more accessible?
Currently, based on the resources that Santa Clara University can provide, our product
does make microinjection more accessible. However, increased accessibility and usage
allows for potential misuse. Similarly, our product comes with multiple tradeoffs,
revealing that a researcher’s location impacts accessibility more than anything else.
3.1

Required facilities and equipment
Our product requires multiple facilities and a variety of equipment: research
location determines feasibility of use. If one already can conduct C. elegans
microinjections, the individual would still require a significant amount of
resources to be capable of using our product.
The microfluidics side of our product requires a cleanroom, and lots of equipment
to accompany it (spin coaters, a mask aligner, volatile chemicals, etc.). The
product also requires a microfluidic multiplexer, multiple air and vacuum sources,
and the accompanying software to make the multiplexer work.
Santa Clara University is fortunate to already have all of these facilities and
materials, no new equipment has needed to be purchased to make our device
work. If a C. elegans researcher find themselves in a similar position, then this
product will work for them. Current prototypes are capable of injecting over
twelve worms per use, compared to three for traditional methods. Our chip also
has the unique ability to unclog its needles, saving more genetic reagent in
comparison to traditional methods. Finally, our product can be used under any
microscope, freeing microinjection from the inverted microscope. Our product
save time, allowing for more injections, more experiments, and more research.
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However, while other facilities and universities have access to the required
spaces, many C. elegans researchers do not. This is a violation of fairness; our
product can only be used in higher-end research settings. Deciding reparations for
this violation is difficult, the common-good approach would imply that those with
access to our product have a duty to share their findings to those without access.
In the C. elegans research community, people are much more forthcoming with
their findings, but our product does not diminish the barrier between C. elegans
researchers with access to higher end facilities versus those with access to lower
end facilities.
3.2

Required personnel
Our product requires one person for complete fabrication. It does not require
someone with a doctorate, but fabrication of the product relies on someone having
basic knowledge of microfluidics. Hence, the knowledge required to complete
microinjection is less severe.
Our product requires two people to operate. Operation of this device is very
difficult without two people, primarily due to the software that interacts with this
chip. On a per capita basis, our product requires more than traditional methods;
however, it also increases opportunities for a workforce of undergraduate research
students looking for work in labs. Allowing undergraduates to participate in the
research and assist in operations would also afford the PI more time to examine
topics that are less familiar to other students. In general, despite the increase in
personnel, the project as a whole is more accessible to everyone; allowing for
better division of labor and more rapid progress.

3.3

People with unsteady hands
Compared to traditional methods, our product is easier to use for people with
unsteady hands. Operation of the chip requires basic microscopy skills and the
ability to use a computer mouse to interact with the microfluidic software.
Traditional microinjection requires aligning objects on the micron scale and then
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lightly tapping on the back of a needle to perform microinjection. Twitchy
motions on the micromanipulator will prevent alignment of the needle with the
worm’s body, too hard of a tap may result in the development of sepsis in a worm.
4.

Impact of more accessible research
As mentioned in Section 1.2, microinjection is a major rate limiting step for C. elegans
genetics research. Assuming a researcher can access and use our product, they will find
this is no longer then case: microinjections can be performed by anyone, and they can be
performed quickly. Hence pros and cons must be weighed, particularly as it pertains to
the ensuing publications. Overall, our product long term benefits outweigh its immediate
consequences.
4.1

Increased competition
A person capable of performing microinjection already will find more
competition in a field she was previously isolated in. Immediately, this will have a
negative impact to said researcher. Papers and topics that the researcher had
“stored,” awaiting until the researcher had time to address them, may sooner be
addressed by other researchers. This will result in the researcher capable of
microinjection losing a potential paper, while the researchers with new access to
microinjection will gain a paper.
However, this paper would be going from someone with a PhD’s worth of
experience to someone with potentially much less experience. Initial publications
are crucial to an early researcher’s career, but publishable topics are hard to come
by. Thus, a publication from our product could help someone with a master’s or
bachelor’s degree more than someone with a doctorate. While the person with the
doctorate would surely benefit from a publication, she would only be adding to a
presumably impressive resume. Therefore, increased competition as a result of
our product may help lower tiers of researchers and allow papers to have more
impact on a person’s career.

4.2

Increased field advancement
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The doctor that lost a paper to competition can still benefit from our product:
more genetics research in C. elegans will be conducted. The fields of biology and
bioengineering benefit from the idea that research ultimately asks more questions
than it answers. For every newfound understanding of C. elegans genetics as a
result of our product, more questions can be asked, and the understanding of the
model organism increases. Hence, one initial paper lost might be multiple papers
gained. In general, as our understanding of C. elegans genetics increases, so too
will the public’s ability to use this knowledge.
5.

Acceptable Use of our Product
As with all products, the usage of our product in a lab requires ethical considerations. The
usage of the product will vary by experience level, and it is essential to recall that all use
impacts the health of living animals. The user is strongly encouraged to consult the
Biomedical Engineering Society’s (BMES) Code of Ethics prior to using our product.
5.1

Use by an experienced doctor
A primary investigator with experience in microinjection that chooses to use our
product may find the product is more time consuming to use initially. Both the PI
and any students involved will need some familiarity with microfluidics.
However, such education would serve to further the education of everyone.
Education would also prevent any research assistants from being used as mere
operators of a product they do not understand. Usage without teaching stands in
direct conflict with a biomedical engineer’s obligation “to train biomedical
engineering students in proper professional conduct” according to the BMES
Code of Ethics.

5.2

Use by a graduate or undergraduate
Our product increases the genetic engineering accessibility to graduates and
undergraduates; it makes room for people with less experience in the field. There
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are consequences to this reduced knowledge, though, such as sympathy for any C.
elegans animals used in this product may be less for a graduate or undergraduate
in comparison to someone with a doctorate. This lack of sympathy is the result of
presumably less interaction with the animals and may result in mistreatment of the
animals (See Section 5.3).
5.3

Animal rights
Our chip can inject more worms per unit of time, and thus it is also capable of
hurting more worms per unit of time. Though C. elegans populations are easy to
maintain, biomedical engineers “[respect] the rights of […] animal subjects” per
the BMES Code of Ethics. Although the animals are easy to raise, they have a
universal right to not be recklessly hurt and killed. Users of our product have a
duty to uphold this right in the course of their research.
Our product does kill more animals per unit of time, but the procedure that it
conducts kills a smaller proportion of animals in comparison to traditional
methods. The success rate of microinjections is higher, but the user may decide
that the overall losses the product causes are unacceptable.

6.

Product Safety
All users have a right to their own safety and a similar duty to maintain their own and the
safety of others. Our product both introduces and mitigates risks in comparison to
traditional microinjection. While mitigation of existing risks is beneficial to all, the
introduction of some new risks may outweigh whatever mitigation is introduced. The
danger that any of these risks pose is entirely based on user expertise and experience.
6.1

Risks introduced
The majority of the new risks that we introduce are the result of the additional
facilities and equipment that our project requires for fabrication (See Section 3.1).
Our project calls for the use of chemicals that are known to be hazardous (toxic,
flammable), and uses a machine that requires UV light. Exposure to chemicals
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can be mitigated by wearing proper protective equipment (PPE) and following lab
safety protocols, and eyes can be protected from UV exposure. However, other
exposed areas of the skin (mouth, neck, etc.), cannot be protected from the UV
light, and it is recommended that the user face away from the machine during
exposure times.
Our product fabrication also requires that some microinjection equipment be used
in untraditional ways. The micromanipulator and inverted microscope are used to
break micron scale needle tips from traditional microinjection needles. While
protocols have been created to mitigate the risks and handling of these micron
size needle fragments, always consult with the owner of the equipment before
using it as our product directs. PPE should always be worn to avoid fragment
contact with the skin, and eyewear is essential to avoid getting fragments in the
user’s eyes.
No injuries have occurred over the course of this project while completing any
procedures. Despite the risks introduced, current safety protocols in most lab
spaces should be enough to mitigate risks and potential harm.
6.2

Risks mitigated
Our product eliminates multiple dangerous elements required by traditional
microinjection. It no longer requires the user to directly glass with molten sections
and decreases the need for exposed flames in lab. Our product eliminates the
requirement of mouth-pipetting to load genetic material into microinjection
needles. While most of these genetic materials have little immediate risk to a
user’s health, mouth pipetting should always be avoided. Our product also
diminishes the probability that a user impales their hand on a needle when loading
genetic material into a microinjection needle.

6.3

Overall
Traditional methods have higher hazard risk than our final solution. Our solution
introduces new hazards with known safety procedures. Our solution does not
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require that any used chemicals come into even remote contact with the mouth.
Traditional microinjection also has a high probability of physical injury, via either
puncture wounds or burns. It is hard to mitigate the probability of these risks, as
they are necessarily introduced for the sake of traditional microinjection.
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